Abstract
Introduction
One hundred and fifty years after the discovery of immunoglobulins (Ig), their role in disease conditions continues to evolve. Particular focus of interest is the IgGs whose subclasses IgG1, IgG2, IgG3 and IgG4 were discovered in 1950s and comprise 71%, 18%, 8% and 3% of serum IgG concentration, respectively 1 . Recent discovery of the association between IgG4 and autoimmune pancreatitis 2 and the subsequent report of IgG4-associated idiopathic tubulointerstitial nephritis (IgG4-TIN) 3 have renewed interest on the role that IgG4 plays in renal diseases. Distinctive pathological features of IgG4-TIN have been described, including elevated serum IgG4 concentrations, plasma cell-rich tubulointerstitial nephritis with >10 IgG4+ plasma cells/ per high power field in the most concentrated field, tubular basement membrane immune complex deposits by immunofluorescence (IF), immunohistochemistry, and/or electron microscopy 4, 5 . The latest twist is the association of IgG4 with membranous nephropathy (IgG-MN) 6, 7 , a disease entity that is generally associated with circulating antibodies to glomerular antigens and local complement activation by subepithelial immune deposit. Although circumstantial evidences suggest that IgG4 could have a pathogenetic role in MN, the inability of IgG4 to activate complement raises questions about the relevance of IgG4 in the pathogenesis of MN.
Hypothesis
We hypothesise that IgG4 molecules undergo structural perturbations via the dynamic Fab arm exchange phenomenon, which then renders it capable of complement activation and hence a direct role in the pathogenesis of IgG4-related MN.
Evaluation of Hypothesis
Evaluation of the hypothesis is based on a review of renal pathology findings and their interpretation in light of recent knowledge of the physicochemical and biological properties of IgG4. MN is characterised by glomerular subepithelial immune deposits that locally activate complement to cause podocyte injury. M-type phospholipase A2 receptor protein (PLA2R1) expressed on the surface of native glomerular podocytes appear to be the dominant autoantigen, and antibodies to PLA2R1 are found in about 80% of patients with primary MN 8, 9 . Majority of the antibodies are of the IgG4 subclass, and titres of IgG4, but not other subtypes, correlate with baseline proteinuria and remission, suggesting a pathogenetic role of these antibodies 10 . Most of the patients with IgG4-related renal disease have low serum complement levels. Moreover, in renal biopsies of patients with IgG4-TIN, IgG4 deposits (as well as IgG1, IgG2 and IgG3) in the interstitium, Bowman capsule and tubular basement membranes were associated with deposits of C3 3, 11 . In patients with IgG4-MN, IF staining for IgG4 and C3 in the glomerular basement membrane were common findings 7 . In multiple animal models of MN, depletion of complement factors mitigated proteinuria and normalised tubular function 12, 13 . Although these circumstantial evidences suggest a role for complement activation in the formation of immune deposits in IgG4-MN, others have shown that IgG4 does not cause complement activation 14, 15 . There is also evidence that amino acids (Ser331Pro replacement) outside the conserved C1q binding sites may also be involved in complement activation. Furthermore, an important factor in complement activation appears to be N-glycosylation of IgG molecules in the C H 2 domain at Asn297 29, 30 . The N-glycans within the C H 2 domain required for alternate complement activation. The N-glycans are heterogeneous and contain variable terminal sugar residues, which can define whether MBLs (alternate pathway) can recognise Igs through their polysaccharide-recognition domains. When the terminal sugar is N-acetyl-glucosamine, MBL can bind to IgG and activate complements via the lectin (alternate) pathway; when it is galactose, C1q binding (classical) can occur; mannose causes abrogation of C1q binding while agalactosylation results in reduced or no complement activation. Therefore, the dynamic Fab arm exchange can cause structural alterations to the IgG4 molecule enabling it to fine-tune its response at C H 2 glycan level by activating either the classical or alternate pathways.
Conclusion
There is emerging clinical and pathological evidence of a role of IgG4 in complement activation in MN. Evidences suggest that the structural perturbations of the IgG4 molecule may be an important factor in its varying functional abilities. The Fab arm ated with complement activation via the classical pathway; whereas IgG2 and IgG4 are associated with complement activation via alternate and lectin pathways.
Discussion
Although the above evidences support the participation of IgG4 in the activation of the complement pathway, its relative contribution in the co-presence of IgG1 and IgG3 remains to be elucidated. Human IgG subclasses have differing abilities to activate complements, decreasing in the order: IgG3>IgG1>IgG2>IgG4 19, 20 . These differences in binding capability to C1q and FcgR are due to differences in their amino acid residues and inter-heavy chain disulphide bridges in the hinge region of IgG subclasses that restrict antigen-binding fragments Fab-Fab and Fab-Fc flexibility that triggers effector functions, such as complement activation and Fc-receptor binding. IgG4 has a short hinge region and displays only limited flexibility as compared with the other IgG subclasses. IgG4 does have a unique property known as the Fab arm exchange phenomenon, whereby a heavy chain and attached light chain (half-molecule) are exchanged with a heavy-light chain pair from another molecule resulting in bispecific antibodies 21 . These functionally monovalent antibodies are unable to cross-link antigen and have less predilection to form immune complexes 22 . How does then IgG4 activate the complement system? A recent review by Karsten and Kohl provides valuable insights into structural features of Igs that facilitate C1q binding 23 . Accordingly, IgG4 hinge regions may potentially attain greater flexibility through dynamic Fab arm exchange mechanism allowing greater accessibility of C1q to binding sites within the C H 2 (Fc) domain to activate complements [24] [25] [26] . The effect size of this phenomenon is uncertain as little is known about the proportion of IgG4 molecules that actually conflict probably requires the reevaluation of historical data in the light of newer understanding of the properties of IgG4.
Lewis et al. were among the early investigators to study the effects of IgG subclasses involved in immune deposits on the inflammatory and morphological picture that evolves in human glomerulonephritis 16 . In 36 renal biopsy specimens from patients with nephritis, deposits containing large amounts of IgG4 tended to have less inflammatory infiltrate than deposits devoid of this subgroup and were not associated with complement fixation. Recent data, however, suggest that IgG4 has proinflammatory properties. IgG4 from sera of patients with anti-neutrophil cytoplasmic (ANCA)-positive granulomatosis with polyangiitis has been demonstrated to stimulate release of superoxide independent of neutrophil donor and expression of FcgRI, which suggests the capability of activating neutrophils via constitutively expressed FcgRIIa/IIIb or co-ligation of other, unidentified, cell surface molecules 17 . Forty years after Lewis's initial work, Segawa et al. investigated the association between IgG subclasses and complement pathways in paediatric patients with MN 18 . In their study, IF revealed IgG1, IgG3, C1q, C3c,C4d, C4-bp, C5b-9 and CD59 deposits in the glomerular capillary wall in patients with segmental MN (i.e. IgG deposit in a portion of the glomerular capillary wall), suggesting complement activation via the classical pathway. In patients with global MN, deposits of IgG1, IgG2, IgG3, IgG4, C3c, C4d, mannose-binding lectin ligand (MBL), factor B, C4-bp, C5b-9 and CD59 were detected, suggesting complement activation via the alternate and lectin pathways. The intensity of C1q deposits was higher in segmental MN vs. global MN, while the intensity of factor B and MBL was higher in global vs. segmental MN. Thus, it was suggested that IgG1 and IgG3 are associ-exchange allows IgG4 to gain a halfmolecule with a heavy and a lightchain, comprising a C H 2 region with a heterogeneous N-glycan structure with differing terminal sugar moiety that can lead to abrogation or activation of complements via the classical or alternate pathways. MN may be just another endproduct of the newly discovered proinflammatory properties of IgG4. Clearly, much work lies ahead.
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